Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Novo Nordisk has an Earnings ESP of -1.42% and a Zacks Rank #4 (Sell) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. NVO operates under two segments — Diabetes ...

Volkswagen of America today announced the initial pricing and trim for the 2025 Volkswagen ID.4 – here’s the lowdown. Volkswagen has restarted production of the ID.4 at its Chattanooga ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed last Friday at ...

Novo Holdings' $16.5 billion acquisition of US ... Despite that, sales of Ozempic rose 26% to around $4.3 billion in the third quarter of 2024, while Wegovy rocketed 79% to $2.5 billion.

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

After hours: 7:59:50 p.m. EST Loading Chart for NVO ...